Fundraising Fox
/Companies
Sign in

Inovio Pharmaceuticals

NASDAQ: INO

Plymouth Meeting, US · Delaware corporation · 1 known investors

Find your way into Inovio Pharmaceuticals

Sign up to see every warm intro you have to Inovio Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Inovio Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

INOVIO is a biotechnology company developing DNA medicines to treat or prevent disease, with a clinical pipeline focused on HPV-related diseases, oncology, and infectious disease. Its platform uses proprietary CELLECTRA devices to deliver DNA into cells to drive protein expression, generate targeted T cells, or produce monoclonal antibodies.

BiotechHealthtech

Founders & leadership

JJ
J. Jospeh KimFounder
PK
Peter KiesChief Financial Officer
JSJacqueline Shea
Jacqueline SheaPresident & Chief Executive OfficerJacqueline Shea is President and CEO of INOVIO Pharmaceuticals, a biotechnology company developing DNA-based medicines for infectious disease, oncology, and HPV-related conditions. She has held leadership roles in vaccine and therapeutic development organizations.
LHLaurent Humeau
Laurent HumeauChief Scientific Officer
MSMichael Sumner
Michael SumnerChief Medical Officer & Head of Development
SESteve Egge
Steve EggeChief Commercial Officer
DB
David B. WeinerNamed on SEC filing
AC
Ann C. MillerNamed on SEC filing
MC
Morton CollinsNamed on SEC filing
AC
Angel CabreraNamed on SEC filing
SX
Simon X. BenitoNamed on SEC filing
LS
Lota S. ZothNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$19.2M disclosed across 2 rounds · 2019

▶$4MraisedJan 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurent HumeauExecutive Officer
  • J. Jospeh KimExecutive Officer, Director
  • Peter KiesExecutive Officer
  • Angel CabreraDirector
  • Simon X. BenitoDirector
  • Jacqueline SheaExecutive Officer
  • Ann C. MillerDirector
  • David B. WeinerDirector
  • Wendy L. YarnoDirector
  • Lota S. ZothDirector
  • Jay ShepardDirector
Offering amount
$4M
Amount sold
$4M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.2MraisedAug 2019 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Wendy L. YarnoDirector
  • David B. WeinerDirector
  • Ann C. MillerDirector
  • Morton CollinsDirector
  • Angel CabreraDirector
  • Simon X. BenitoDirector
  • Peter KiesExecutive Officer
  • J. Jospeh KimExecutive Officer, Director
  • Jacqueline SheaExecutive Officer
  • Laurent HumeauExecutive Officer
  • Lota S. ZothDirector
Offering amount
$15.2M
Amount sold
$15.2M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
U.S. ArmyArmyPhase II2012$1.3M
U.S. ArmyArmyPhase I2011$69.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Inovio Pharmaceuticals do?
INOVIO is a biotechnology company developing DNA medicines to treat or prevent disease, with a clinical pipeline focused on HPV-related diseases, oncology, and infectious disease. Its platform uses proprietary CELLECTRA devices to deliver DNA into cells to drive protein expression, generate targeted T cells, or produce monoclonal antibodies.
Who founded Inovio Pharmaceuticals?
Inovio Pharmaceuticals was founded by J. Jospeh Kim.
Who are Inovio Pharmaceuticals's investors?
Inovio Pharmaceuticals's investors include Korea Investment Partners.
How much funding has Inovio Pharmaceuticals raised?
Inovio Pharmaceuticals has disclosed $19.2M raised across 2 rounds.
Where is Inovio Pharmaceuticals headquartered?
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, US.